161 related articles for article (PubMed ID: 33901791)
1. Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma.
Boutros C; Rouleau E; Majer M; Nikolaev S; Robert C
Eur J Cancer; 2021 Jun; 150():130-132. PubMed ID: 33901791
[No Abstract] [Full Text] [Related]
2. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum.
Fife D; Laitinen MA; Myers DJ; Landsteiner PB
Pediatr Dermatol; 2017 Mar; 34(2):163-165. PubMed ID: 28297142
[TBL] [Abstract][Full Text] [Related]
4. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
5. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin.
Gathings RM; Orscheln CS; Huang WW
J Am Acad Dermatol; 2014 Apr; 70(4):e88-e89. PubMed ID: 24629372
[No Abstract] [Full Text] [Related]
6. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.
Iarrobino A; Messina JL; Kudchadkar R; Sondak VK
J Am Acad Dermatol; 2013 Jul; 69(1):e33-4. PubMed ID: 23768306
[No Abstract] [Full Text] [Related]
7. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
Ighilahriz M; Benfodda M; Sharpe H; Soufir N; Mourah S; Dumaz N; Battistella M; Savina A; Bouquet F; Nikolaev S; Basset-Seguin N
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e422-e424. PubMed ID: 31187903
[No Abstract] [Full Text] [Related]
8. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
[TBL] [Abstract][Full Text] [Related]
9. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
Sarkis J; Khalil N; Alkassis M
Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
[No Abstract] [Full Text] [Related]
10. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
[No Abstract] [Full Text] [Related]
11. Excellent response of basal cell carcinomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream.
Nagore E; Sevila A; Sanmartin O; Botella-Estrada R; Requena C; Serra-Guillen C; Sanchez-Pedreño P; Guillen C
Br J Dermatol; 2003 Oct; 149(4):858-61. PubMed ID: 14616381
[TBL] [Abstract][Full Text] [Related]
12. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
Kaehler KC; Gutzmer R; Egberts F; Hauschild A
J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
[No Abstract] [Full Text] [Related]
13. Vismodegib in the treatment of advanced BCC.
O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
[TBL] [Abstract][Full Text] [Related]
14. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
15. Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: case report.
Saade M; Debahy NE; Houjeily S
J Chemother; 1999 Aug; 11(4):313-7. PubMed ID: 10465136
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.
Koelblinger P; Dummer R; Laimer M; Hecht S; Bauer JW; Gaggl A; Kugler A
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e7-e8. PubMed ID: 28646606
[No Abstract] [Full Text] [Related]
17. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma.
Paulsen JF; Øregaard JS; Nielsen AL; Gehl J; Venzo A
Acta Oncol; 2016 Dec; 55(12):1492-1494. PubMed ID: 27448604
[No Abstract] [Full Text] [Related]
18. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.
Ameri AH; Mooradian MJ; Emerick KS; Park JC; Wirth LJ; Asgari MM; Tsao H; Lawrence D; Sullivan RJ; Demehri S
Br J Dermatol; 2019 Nov; 181(5):1095-1097. PubMed ID: 31102460
[No Abstract] [Full Text] [Related]
19. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
Nayyar PM; Chang ALS; Sarin K; Ratner D
Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109
[No Abstract] [Full Text] [Related]
20. Histologic Findings of Tumor Lysis in Advanced Basal Cell Carcinoma Treated With Vismodegib.
Powell EM; Stratton JS; Shendrik I; Blalock TW
Dermatol Surg; 2016 Jul; 42(7):904-7. PubMed ID: 27191782
[No Abstract] [Full Text] [Related]
[Next] [New Search]
